Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247726 · ClinicalTrials.gov registry record · Phase 2
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT02247726: Completed Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Novavax.
NCT02247726 is a Phase 2 study of Respiratory Syncytial Virus Infections that has completed, run by Novavax. The registered enrollment target is 50 participants, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02247726, a Phase 2 study of Respiratory Syncytial Virus Infections, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.
Primary Outcome
In Maternal Subjects
Conditions Studied
Interventions
- DRUG Saline Placebo (0.5mL injection)
- DRUG RSV F vaccine (0.5mL injection)
Study Locations (7)
Kansas
- Hutchinson Clinic, P.A. - Hutchinson
- University of Kansas Medical Center Research Institute - Kansas City
Idaho
- Advanced Specialty Research - Nampa
Nebraska
- Meridian Clinical Research - Norfolk
North Carolina
- Duke University - Durham
Pennsylvania
- Magee- Womens Hospital of UPMC - Pittsburgh
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
What the finished NCT02247726 record still lists
NCT02247726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Saline Placebo (0.5mL injection) is the first listed.
NCT02247726 lists 7 locations in 6 states (Kansas, Idaho, Nebraska).
Frequently Asked Questions
What is clinical trial NCT02247726 about?
NCT02247726 is a clinical study titled "RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.". The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.
What is the current status of trial NCT02247726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-09. Estimated completion is 2016-07.
What conditions does trial NCT02247726 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT02247726?
The interventions under investigation include: Saline Placebo (0.5mL injection) (DRUG), RSV F vaccine (0.5mL injection) (DRUG).
Who is sponsoring clinical trial NCT02247726?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02247726 being conducted?
This trial has 7 study locations across Idaho, Kansas, Nebraska, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02247726's enrollment target sits among peer trials
50 19th of 21 higher than 2 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
RECRUITING · Phase 2
-
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
RECRUITING · Phase 2
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
COMPLETED · Phase 2
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia